Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Chugai

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Chugai's Japan sales performance.

Bayer bags FDA nod for early prostate cancer drug darolutamide

Bayer bags FDA nod for early prostate cancer drug darolutamide Bayer says it has also submitted darolutamide in the EU, Japan, and additional countries around the world.

CHMP backs Bayer’s tumour-agnostic drug Vitrakvi

CHMP backs Bayer’s tumour-agnostic drug Vitrakvi Entrectinib has just been approved in Japan, its first market, as Rozlytrek.

ACPs to lead gene therapies in haemophilia market growth

ACPs to lead gene therapies in haemophilia market growth GlobalData found that key opinion leaders in the eight major markets (the US, France, Germany, Italy, Spain, UK, Japan, and China) are highly optimistic about these therapies and agree that they

Metavant/Poxel prep phase 3 for imeglimin in diabetic kidney disease

Metavant/Poxel prep phase 3 for imeglimin in diabetic kidney disease trial programme for imeglimin outside Japan, where two phase 3 studies have already generated positive results in diabetes. ... drug. The French company signed an agreement with Sumitomo Dainippon Pharma in 2017 for development rights to the drug in

LADbible Campaign

by Hanover Communications for Roche Chugai. A key objective for Roche/Chugai’s public affairs activity in 2018 was to support shaping the haemophilia landscape, as well as to position itself ... Using Instagram and collaborating with LADbible opened a

[ Previous 5 results ] 5 6 7 8 9 10 11 12 13 14 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Videum Health

Videum Health is a premium video platform that offers brands innovative engagement strategies to reach targeted healthcare audiences on a...

Latest intelligence

The balancing act that’s keeping pharma and biotech market access on its toes
Pricing drugs and gaining reimbursement can be a real challenge for drug developers. Price it too high, and no one buys it. Price it too low, and it’s hard to...
Pills
Tackling antimicrobial resistance on multiple fronts
An urgent change of direction is needed in how we respond to AMR...
Happy Chinese New Year 2020 - The Year of The Rat
A fond farewell to The Year of the Pig...

Infographics